Advanced Filters
noise

Glendale, Wisconsin Clinical Trials

A listing of Glendale, Wisconsin clinical trials actively recruiting patient volunteers.

Found 364 clinical trials
W Wellstar Research Institute

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to …

18 years of age All Phase 3
M Mariah Palmer

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.

12 - 18 years of age All Phase 3
O Olga Taraschenko, MD, PhD

FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human …

18 - 75 years of age All Phase 1/2
M Meredith Beversdorf, RN

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. …

- 25 years of age All Phase 2

Percutaneous Neurostimulation to Treat Paroxysmal Sympathetic Hyperactivity in Children

Survivors of severe brain injury, such as lack of oxygen or severe traumatic brain injury, frequently experience Paroxysmal Sympathetic Hyperactivity (PSH). PSH is characterized by disabling symptoms such as a fast heart rate, high blood pressure, rapid breathing, rigidity, tremors, and sweating due to uncontrolled sympathetic hyperactivity in the nervous …

2 - 17 years of age All Phase N/A
S Site Public Contact

Venetoclax to Augment Epigenetic Modification and Chemotherapy

The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.

1 - 25 years of age All Phase 1
W William Hughes, Ph.D.

Heat, Microvascular Function and Aging

Vascular dysfunction is a common factor in many chronic debilitating diseases, contributing to morbidity and mortality. With the onset of chronic disease or exposure to stress, the vasculature displays an inability to adequately respond to increased blood flow demands, manifesting in a reduced ability or altered mechanism of vasodilation. Aging …

18 - 80 years of age All Phase N/A
J Jenya Iuzzini-Seigel, PhD

Exercise Training in Children With Communication Impairments

This clinical trial study has two goals. The first goal is to establish fitness levels, participation in physical activities, and fine/gross motor abilities for children with development language disorder (DLD). DLD occurs in 1/13 children and children with DLD often have poorer fine/gross motor skills than those with typical development. …

5 - 9 years of age All Phase N/A

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

13 years of age All Phase 3
R Rawan Faramand, MD

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.

3 - 75 years of age All Phase 2

Simplify language using AI